Literature DB >> 17351766

Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930-936.

D Raccah.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17351766     DOI： 10.1007/s00125-007-0630-3

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  10 in total

1.  Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930-936.

Authors:  J A Tayek
Journal:  Diabetologia       Date:  2006-09-06       Impact factor: 10.122

2.  Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.

Authors:  Scot H Simpson; Sumit R Majumdar; Ross T Tsuyuki; Dean T Eurich; Jeffrey A Johnson
Journal:  CMAJ       Date:  2006-01-17       Impact factor: 8.262

3.  Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  D M Nathan; J B Buse; M B Davidson; R J Heine; R R Holman; R Sherwin; B Zinman
Journal:  Diabetologia       Date:  2006-08       Impact factor: 10.122

4.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

Authors:  Steven E Kahn; Steven M Haffner; Mark A Heise; William H Herman; Rury R Holman; Nigel P Jones; Barbara G Kravitz; John M Lachin; M Colleen O'Neill; Bernard Zinman; Giancarlo Viberti
Journal:  N Engl J Med       Date:  2006-12-04       Impact factor: 91.245

5.  The UGDP study.

Authors:  D S Salsburg
Journal:  JAMA       Date:  1971-12-13       Impact factor: 56.272

6.  Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes.

Authors:  J A Johnson; S H Simpson; E L Toth; S R Majumdar
Journal:  Diabet Med       Date:  2005-04       Impact factor: 4.359

7.  Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study.

Authors:  J Olsson; G Lindberg; M Gottsäter; K Lindwall; A Sjöstrand; A Tisell; A Melander
Journal:  Diabetologia       Date:  2000-05       Impact factor: 10.122

8.  Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

Authors:  Jeffrey A Johnson; Sumit R Majumdar; Scot H Simpson; Ellen L Toth
Journal:  Diabetes Care       Date:  2002-12       Impact factor: 19.112

9.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.

Authors:  J M M Evans; S A Ogston; A Emslie-Smith; A D Morris
Journal:  Diabetologia       Date:  2006-03-09       Impact factor: 10.122
  10 in total
  3 in total

1.  Changes in Type 2 Diabetes Mellitus Patients in German Primary Care Prior to (2006) and After (2010, 2014) Launch of New Drugs.

Authors:  Louis Jacob; Lilia Waehlert; Karel Kostev
Journal:  J Diabetes Sci Technol       Date:  2016-02-10

2.  No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis.

Authors:  Josie M M Evans; Simon A Ogston; Frank Reimann; Fiona M Gribble; Andrew D Morris; Ewan R Pearson
Journal:  Diabetes Obes Metab       Date:  2007-12-17       Impact factor: 6.577

3.  Real-world Evaluation of glycemic control and hypoglycemic Events among type 2 Diabetes mellitus study (REEDS): a multicentre, cross-sectional study in Thailand.

Authors:  Bancha Satirapoj; Thongchai Pratipanawatr; Boonsong Ongphiphadhanakul; Sompongse Suwanwalaikorn; Yupin Benjasuratwong; Wannee Nitiyanant
Journal:  BMJ Open       Date:  2020-02-12       Impact factor: 2.692
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.